pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases

© Khairuddin Djawad

Hasanuddin University, Indonesia Faculty of Medicine
Jl. Perintis Kemerdekaan Km.10, 90245, Indonesia, Makassar

Introduction. Morbus Hansen is the infectious disease which causes by bacilli intracellular Mycobacterium leprae which mainly affects the skin and peripheral nerves. The leprosy reaction is an episode an immunologically mediated episode of acute or subacute inflammation which affecting skin, nerve, mucous membrane. Type 2 reactions can be last for months and risk of developing dependence on steroids. Pentoxifylline (PTX) works to hampers the production TNFα in vitro and in vivo, are an alternative for ENL treatment.

Case Report. One case was reported in a male aged 28 years with complaints of recurring red bumps accompanied by fever and pain.

Discussion. On physical examination obtained erythema nodosum, with impaired sensibility in the left leg. The patient experienced improvement after being given therapy of neurodex/24 hours/oral, rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg which given 3x for a week, and combination therapy to treat the Leprosy reaction given the combination of methylprednisolone 16mg (3-2-0) and Pentoxifylline 400 mg/8 hours/oral.

Conclusion. In the 21 day of treatment, the redness lump improved in the middle finger and left arm was gone. No new reddish bumps appeared and less tingling sensation.

Keywords: morbus hansen, erythema nodosum leprosum, pentoxifylline, steroid dependence, leprosy reaction.

For citation: Khairuddin Djawad. Pentoxifylline therapy for patients with type 2 leprosy reactions: erythema nodosum leprosum in steroid-dependent cases. Vestnik Dermatologii i Venerologii. 2021;97(1):46–53.
doi: https://doi.org/10.25208/vdv1196
Leprosy or Morbus Hansen is the infectious disease which causes by intracellular Bacilli *Mycobacterium Leprae* which mainly affects the skin and peripheral nerves. The clinical manifestations of leprosy are classified into five types: *tuberculoid* (TT), *borderline tuberculoid* (BT), *borderline* (BB), *borderline lepromatous* (BL) dan *lepromatous* (LL). This classification is made by Ridley-Jopling based on the clinical, histological and immunological differences in disease [1].

The last year of 2015, prevalence is calculated become 0,29 (174,608 cases) per 100.000 population, and the new cases level is counted become 3,2 (210,758 cases) per 100.000 population, it obtained from the data collection by WHO in 138 countries according to patients receiving MDT [2] Most age prevalence is in leprosy at the age of 30–50 years, where there are more men than women [3].

The leprosy reaction is an episode an immunologically mediated episode of acute or subacute inflammation which affecting skin, nerve, mucous membrane. It found 2 types of reaction which occurs for leprosy: reaction of type 1 (T1R) or reversal reaction (RR), which is type 4 hypersensitivity, mostly occur in tuberculoid patients (BT), borderline patient (BB) and borderline lepromatous (BL) it is rarely happens to type lepromatous leprosy (LL). Reactions of Type 2 (T2R) or Erythema Nodosum Leprosum (ENL) is the hypersensitivity reaction type III, it is commonly happening to LL and sometimes to BL patient. According to [4] Several patients with ENL reaction having mild episodes of general malaise, multiple red skin nodules that may recur, may be accompanied by edema of the hands and feet, skin nodules especially in the upper and lower extremities, pain (neuritis) and orchitis. ENL is sometimes found can be found in untreated BL-LL patients or in patients undergoing treatment [5].

Type 2 reaction can often for months and found there is a risk of developing steroid dependence. Moreover, it is given combination therapy of prednisolone 1 mg / kg BW and clofazimine dosage and/or with thalidomide. Clofamazine given together with corticosteroid to every cases with the first dosage 100 mg/8 hours/oral during 12 weeks, the second dosage 100 mg/12 hours/oral and third dosage 100 mg/24 hours/oral. Clofazimine has a less potent effect than steroids taking 4–6 weeks to take full effect. However, it is useful for preventing dependence on steroids. The total duration of clofazimine therapy should not exceed 12 months [6].

ENL is related with the serum necrosis factor-alpha levels (TNFa) highest serum, it shows that cytokine is also play a central role in the manifestation of ENL. Thalidomide (TH) and systemic steroid (S), both are inhibitor production of TNFa, and the two effective medicines nowadays to managing ENL. Nowadays, Pentoxifylline (PTX), which also prevent the TNFa production in vitro and in vivo, which has suggested to ENL treatment. It has implemented the research, for 15 PTX cases which given 800 mg/8 hours/oral to 2 cases or 400 mg/8 hours/oral to 13 cases. Recurrence occurred within 2-3 months in 5 patients, if the PTX usage is suddenly stopped. However, there was no recurrence in patients who went through gradually decreasing the PTX dose. Recurring ENL episodes have also responded well to PTX [7].

Cases report

28 years old man with RM854616 comes with the symptom appear red bumps on the right and left arms, on the neck since the morning, complaints accompanied by fever (Fig. 1a, b). Since 1 year before coming to hospital, red bumps come and go almost all over the body, which is painful, accompanied by fever and joint pain. Previously, red bumps are appears in body then multiplied and expanded to both arms and legs. If the complaint worsens, the entire joint cannot be moved due to pain.

History of suffering from leprosy since 2016, MDT treatment was complete for 1 year at the health center and BTA negative at the end of treatment, the patient was said to have recovered from leprosy. 6 months later then the patient felt numbness of the skin on the left leg accompanied by several painful red lumps on the trunk, arms and legs. Patient then brings to RSUD Manokwari hospital with therapy of prednisione tablet 5 mg (6-0-2). Every tablet prednisone the dosage is reduced become 4-0-2, complaints came back. During 3 months the patient underwent treatment like this but did not improve, the patient brings to dermatology and venereology polyclinic of Hasanuddin Hospital.

In Hasanuddin Hospital polyclinic on August, implements the BTA examination and biopsy was carried out, it was found that the leprosy germs were presented. Patient then given the ROM treatment 3x/week and prednisone, but 10 days after patient occur fever and pain throughout the body accompanied by several red lumps on the right and left arms, on the neck and the skin on the left leg.

Figure Information: (a, b) Status localis of the left upper limb region, efflorescence of erythema nodules and hyperpigmented macules.

Figure 1. Day 1 at the time of entering the hospital
joint. Patient then brings to Wahidin Hospital, until now the complaint is the form of red bumps almost all over the body sometimes it still appears.

In the past, the patient did not have a history of hypertension and had no history of diabetes. On physical examination, he found a good general condition, composition awareness, and vital signs: blood pressure 120/80 mmHg, pulse 84 x/minute, breathing 18 x/minute, temperature 38.8°C, height 160 cm and weight 65 kg. In the dermatological examination to regio facialis obtained efflorescence is in the form of edema, in the regio generalisata obtained efflorescence in the form of multiple nodules erythema. No peripheral nerve enlargement was found, in the sensibility examination obtained hypoesthesia in the left leg from the tip of the foot to mid-femoral level, there are no motor weaknesses.

In the laboratory examination obtained WBC 10.000, HGB 14, PLT 389.000, PT 11, APTT 23, Sodium 138, Potassium 3.7, Chloride 101. In the slit examination skin smear and obtained the result on right ear +1, left ear +3, and on the lesion +1.

On examination, biopsy support on tube I is shown an atrophic epidermis with a clear zone area. In the upper dermis to the subcutis fat layer found granuloma which commonly follows adnexal skin and nerve fibers consist of the histiocyte cells with foamy cytoplasm and neutrophil inflammatory cells in between (Fig. 2a, b). On the Fite-Faraco staining, the result is positive (Fig. 2c, d). In the tube II shows the epidermis which looks atrophy with clear zone area. In the upper dermis to the lower dermis found granuloma which following skin adnexitis and nerve fibers consist of histiocyte cells with foamy cytoplasm and neutrophil inflammatory cells in between (Fig. 3a). Fite-Faraco staining obtained positive results (Fig. 3b). Morbus Hansen impressions of Lepromatous leprosy type with Erythema Nodosum Leprosum reactions.
Based on the anamnesis, physical and supporting examination so the last diagnosed of patient with Morbus Hansen type Lepromatous leprosy with Leprosy reaction type II Erythema Nodosum Leprosum. Patient was given 20 drops of Ringers lactate infusion therapy per minute, Rifampicin 600 mg, Ofloxacin 400 mg, Minocycline 100 mg (twice a week), methylprednisolone 8 mg (2-1-0) and paracetamol 500 mg/8 hours/oral if fever.

In the 13 days treatment, it found a raised red lump on the middle finger and left arm accompanied by pain (Fig. 4). The complaint accompanied with pain and redness on scrotum area, there is fever and a tingling feeling. In the dermatologic examination on regio facialis it found efflorescence in the form of edema, regio generalisata found efflorescence in the form of multiple Nodule erythema. In the sensitivity examination still found the hypoesthesia is still found in the left leg from the tip of the foot to the mid-femoral level.

Patient was given Ringer's lactate infusion therapy 20 drops per minute, intravenous neurobion drip (2x a week), rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg (3x a week), paracetamol 500 mg/8 hours/ oral if fever and treatment for leprosy reaction given Pentoxifylline 400 mg/8 hour/oral (day 1) combination with methylprednisolone 16 mg (3-2-0) day 5.

In the day 15 of treatment, it found redness lump improved on the middle finger and left arm accompanied by pain, no new reddish bumps appeared (Fig. 5). The complaint including pain, and redness on the scrotum area is reduced, tingling feeling is reduced. On the dermatology examination on regio facialis found efflorescence in the form of edema, on regio generalisata found efflorescence in the form of multiple nodules erythema. On the sensibility examination still obtained hypoesthesia in the left leg from the tip of the foot to the mid-femoral level.

Patient was given Ringer's lactate infusion therapy 20 drops per minute, intravenous neurobion drip (2x a week), rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg (3x a week), paracetamol 500 mg/8 hours/ oral if fever and treatment for leprosy reaction given Pentoxifylline 400 mg/8 hour/oral (day 3) combination with methylprednisolone 16 mg (3-2-0) day 7.

In the 16 days of treatment, it found redness lump improved on the middle finger and left arm accompanied by pain, no new reddish bumps appeared (Fig. 6). The complaint including pain, and redness on the scrotum area is reduced, tingling feeling is reduced. On the dermatology examination on regio facialis found efflorescence in the form of edema, on regio generalisata found efflorescence in the form of multiple nodules erythema. On the sensibility examination still obtained hypoesthesia in the left leg from the tip of the foot to the mid-femoral level.

Patient was given Ringer's lactate infusion therapy 20 drops per minute, intravenous neurobion drip (2x a week), rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg (3x a week), paracetamol 500 mg/8 hours/ oral if fever and treatment for leprosy reaction given Pentoxifylline 400 mg/8 hour/oral (day 4) combination with methylprednisolone 16 mg (3-2-0) day 8.

In the 17 days of treatment, it found redness lump improved on the middle finger and left arm accompanied by pain, no new reddish bumps appeared (Fig. 7). The complaint including pain, and redness on the scrotum area is reduced, tingling feeling is reduced. On the dermatology examination on regio facialis found efflorescence in the
form of edema, on regio generalisata found efflorescence in the form of macula hyper-pigmentation. On the sensibility examination still obtained hypoesthesia in the left leg from the tip of the foot to the mid-femoral level.

Patient was given Ringer’s lactate infusion therapy 20 drops per minute, Neurobion drip intravenous (2x a week), rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg (3x a week), paracetamol 500 mg/8 hours/ oral if fever and treatment for leprosy reaction given Pentoxifylline 400 mg/8 hour/oral (day 6) combination with methylprednisolone 16 mg (3-2-0) day 10.

In the 21 days of treatment, it found redness lump improved on the middle finger and left arm accompanied by pain, no new reddish bumps appeared (Fig. 9). The complaint including pain, and redness on the scrotum area is reduced, tingling feeling is reduced. On the dermatology examination on regio facialis found efflorescence in the form of edema, on regio generalisata found efflorescence in the form of petechiae and hyper-pigmented macules. On the sensibility examination still obtained hypoesthesia in the left leg from the tip of the foot to the mid-femoral level.

Patient was given Ringer’s lactate infusion therapy 20 drops per minute, Neurobion drip intravenous (2x a week), rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg (3x a week), paracetamol 500 mg/8 hours/oral if fever and treatment for leprosy reaction given Pentoxifylline 400 mg/8 hour/oral (day 9) combination with methylprednisolone 16 mg (3-2-0) day 13.
The next therapy implements the decreased dose after administration Pentoxifylline 400 mg/12 hours/oral day 5, become Pentoxifylline 400 mg/24 hours/oral and after 5 days the Pentoxifylline was stopped.

Discussion
Diagnose of Morbus Hansen type Lepromatous leprosy with leprosy reaction Erythema nodosum leprosum. In this patient, it is enforced from the history, physical examination and investigation. From anamnesis it obtained the complaints arise redness bumps on the right and left arms and on the neck since the morning. Complaints accompanied by fever. Since 1 year before comes to Hospital, the redness bumps is disappear and cause almost the entire body, pain feelings, with fever and joint pain. Previously, the redness bumps appear in body then multiple and spreading on both leg and both limbs. If the complaint is severe, the entire joint cannot be moved due to pain.

In accordance with literature the leprosy reaction seen on 50% patient and can causes the rapid nerve damage resulting in anesthesia and weakness [8]. It found two types of leprosy reaction which is: type 1 reaction (T1R, reversal reaction) and type 2 reaction (Erythema nodosum leprosum, ENL) [9]. Based on the distribution from the type of leprosy reactions above on patients includes leprosy reaction types of Erythema nodosum leprosum. Type 2 reactions mostly occur during anti-leprosy treatment. Some cases of leprosy reaction appear first time during the beginning of the treatment. The data collected by IAL of 2003 both field and Hospital shows that 21% of all cases with ENL lesions, 17.6% attended within 6 months of starting MDT, 16.6% during a year usage of MDT, and 44.5% more than a year of therapy. A study of Chandigarh also shows the same number, 19.4% (BL) and 20.1% (LL) [10].

In the anamnesis and physical examination found the redness bumps in both limbs that appeared after 6 months of complete MDT treatment. The Complaints accompanied by pain in the area of the lesion, fever and joint pain. According to ENL literature can happen at any time, by pain in the area of the lesion, fever and joint pain. Previously, the redness bumps in body then multiple and spreading on both leg and both limbs. If the complaint is severe, the entire joint cannot be moved due to pain.

In accordance with literature the leprosy reaction seen on 50% patient and can causes the rapid nerve damage resulting in anesthesia and weakness [8]. It found two types of leprosy reaction which is: type 1 reaction (T1R, reversal reaction) and type 2 reaction (Erythema nodosum leprosum, ENL) [9]. Based on the distribution from the type of leprosy reactions above on patients includes leprosy reaction types of Erythema nodosum leprosum. Type 2 reactions mostly occur during anti-leprosy treatment. Some cases of leprosy reaction appear first time during the beginning of the treatment. The data collected by IAL of 2003 both field and Hospital shows that 21% of all cases with ENL lesions, 17.6% attended within 6 months of starting MDT, 16.6% during a year usage of MDT, and 44.5% more than a year of therapy. A study of Chandigarh also shows the same number, 19.4% (BL) and 20.1% (LL) [10].

In the anamnesis and physical examination found the redness bumps in both limbs that appeared after 6 months of complete MDT treatment. The Complaints accompanied by pain in the area of the lesion, fever and joint pain. According to ENL literature can happen at any time, by pain in the area of the lesion, fever and joint pain. Previously, the redness bumps in body then multiple and spreading on both leg and both limbs. If the complaint is severe, the entire joint cannot be moved due to pain.

In accordance with literature the leprosy reaction seen on 50% patient and can causes the rapid nerve damage resulting in anesthesia and weakness [8]. It found two types of leprosy reaction which is: type 1 reaction (T1R, reversal reaction) and type 2 reaction (Erythema nodosum leprosum, ENL) [9]. Based on the distribution from the type of leprosy reactions above on patients includes leprosy reaction types of Erythema nodosum leprosum. Type 2 reactions mostly occur during anti-leprosy treatment. Some cases of leprosy reaction appear first time during the beginning of the treatment. The data collected by IAL of 2003 both field and Hospital shows that 21% of all cases with ENL lesions, 17.6% attended within 6 months of starting MDT, 16.6% during a year usage of MDT, and 44.5% more than a year of therapy. A study of Chandigarh also shows the same number, 19.4% (BL) and 20.1% (LL) [10].

In the anamnesis and physical examination found the redness bumps in both limbs that appeared after 6 months of complete MDT treatment. The Complaints accompanied by pain in the area of the lesion, fever and joint pain. According to ENL literature can happen at any time, by pain in the area of the lesion, fever and joint pain. Previously, the redness bumps in body then multiple and spreading on both leg and both limbs. If the complaint is severe, the entire joint cannot be moved due to pain.

In accordance with literature the leprosy reaction seen on 50% patient and can causes the rapid nerve damage resulting in anesthesia and weakness [8]. It found two types of leprosy reaction which is: type 1 reaction (T1R, reversal reaction) and type 2 reaction (Erythema nodosum leprosum, ENL) [9]. Based on the distribution from the type of leprosy reactions above on patients includes leprosy reaction types of Erythema nodosum leprosum. Type 2 reactions mostly occur during anti-leprosy treatment. Some cases of leprosy reaction appear first time during the beginning of the treatment. The data collected by IAL of 2003 both field and Hospital shows that 21% of all cases with ENL lesions, 17.6% attended within 6 months of starting MDT, 16.6% during a year usage of MDT, and 44.5% more than a year of therapy. A study of Chandigarh also shows the same number, 19.4% (BL) and 20.1% (LL) [10].

In the anamnesis and physical examination found the redness bumps in both limbs that appeared after 6 months of complete MDT treatment. The Complaints accompanied by pain in the area of the lesion, fever and joint pain. According to ENL literature can happen at any time, by pain in the area of the lesion, fever and joint pain. Previously, the redness bumps in body then multiple and spreading on both leg and both limbs. If the complaint is severe, the entire joint cannot be moved due to pain.
In accordance with corticosteroid literature, the first-line therapy in the management of ENL. They are acts with inhibit the first phase and end of inflammation. Corticosteroids decrease chemotaxis of neutrophils and inhibit prostaglandin synthetase enzyme. Giving steroid is also related with suppression of cell-mediated immunity (CMI) especially helper T cells. WHO recommended prednisolone started from 1 mg/kg BW/days to clinical improvement, and then lowered every week by 5–10 mg for 6–8 weeks. Maintenance dosage 20-30 mg might be needed during a week to prevent repeat ENL. The steroid dependence is the important problem to noticed, but reduce the steroid dosage is often related with recurrent reaction [12].

Patient is given ROM regiment to treat multibacillary leprosy. In accordance with literature, on 1997, the combination rifampicin (600 mg), ofloxacin (400 mg) and minocycline (100 mg) as ROM therapy accepted for Paucibacilller Leprosy (PB) single lesion (WHO). In the end 1990, a research related the usage of ROM therapy and some of which also include multibacillary leprosy. Ofloxacin and minocycline with strong bactericidal activity on M. leprae. For Leprosy MB can be suggested for refuses patient or it cannot be used for MDT. ROM is safety and effective such as MDT, it does not cause skin pigmentation, and give the clinical improvement, bacteriology, and the same histology, as MDT, it does not cause skin pigmentation, and give the clinical improvement, bacteriology, and the same histology, without improving the Lepra reaction level. But, the ROM price is four times more than MDT for the same regimen duration [20].

Pentoxifylline 400 mg/8 hours/oral in this cases used as leprosy reaction treatment, according with Pentoxifylline literature is derive methylxantine which have the antihemorrhagic activity and used in the conditions where there are microcirculation defects as well as where TNF-α roles on the occurrence of the diseases. Giving PTX oral in the ENL sufferers can inhibit cytokine syntheses in monocytes, between TNF-α, IL-1, IL-6, IL-8 and IL-12. [7]. Pentoxifylline has succeeded used in type II reactions with the significant clinical improvement during period of 2 weeks. Pentoxifylline dosage is 400 mg every 8 hours, combined with Prednisone dosage 0.5 mg/kg/day. If clinical improvement occurs, after 30 days, prednisone dosage reduced gradually, and Pentoxifylline is maintained for another two to three months [21].

The other therapy is given Neurodex®/24 hours/oral which consist of Vitamin B1 mononitrate 100 mg, vitamin B6 HCl 200 mg, vitamin B12 200 mcg. In accordance with the literature is called that Vitamin B complex helps to relieve degeneration in the nerve system and Vitamin B1 (thiamin), Vitamin B6 (pyridoxine) in the combination with Vitamin B12 in clinically can be administered [22]. Vitamin B12 especially shows the important role in several biologic accidents to maintain normal nerve function [22-23]. The application B complex or Vitamin B12 has proven to improve the total Schwann cells and fiber nerves of myelin and Axon diameter and thus triggered regeneration of myelin nerve fibers and proliferation of Schwann cells [24].

Conclusion

Morbus Hansen Diagnose types of Lepromatous leprosy with Leprosy reaction Erythema nodosum leprosum. In this patient it is enforced from the anamnesis, physical examination and supporting investigation. From the anamnesis the found complaint is appears the redness bumps on both arms with neck since morning. The complaints accompanied by fever, in the physical examination found erythema nodules, with impaired sensibility in the left leg. The patient experienced improvement after being given neurodex therapy/24 hours/oral, rifampicin 600 mg, ofloxacin 400 mg, minocycline 100 mg which given 3x a week, and combination therapy for leprosy reaction treatment is given the combination of methylprednisolone 1 mg (3-2-0) and Pentoxifylline 400 mg/8 hours/ oral. In the 21 day of treatment, the redness lump improved in the middle finger and left arm was gone. No new reddish bumps appeared and less tingling sensation.

References

1. Rodrigues LC, Lockwood DNj. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11(6):464–470. doi: 10.1016/S1473-3099(11)70006-8
2. World Health Organization. "Global leprosy update, 2015: time for action, accountability and inclusion., Relev Epidemiol Hebd, 2015;2:91(35):405–420. English, French. doi: 10.1186/1750-9378-2-15.Voir
3. Zaenglein AL, Graber EM. Fitzpatrick's Dermatology in general medicine In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. 8th ed.; New York: McGraw-Hill; 2012.
4. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol 2014;24;71(4):795–803. doi: 10.1016/j.jaad.2014.03.034
5. Pulido-Pérez A, Suárez Fernández R. Leprosy reactions and their management. Piel. 2015;30(10). doi: 10.1016/piel.2015.04.015
6. World Health Organization. Leprosy Reaction and its Management. 2013.
7. de Carsalade GY, Achirafi A, Flageul B. Efficacité de la Pentoxifylline dans le traitement de l’erythème noueux lépréux: résultats d’une étude ouverte [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. Acta Leprol. 2004;12(3):117–22 (In French)
8. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2008;19(2):338–381. doi: 10.1128/CMR.19.2.338-381.2008
9. Britton WJ, Lockwood DNJ. Leprosy. The Lancet. 2004;363(9416):1209–1219. doi: 10.1016/S0140-6736(04)15952-7
10. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119–125. doi: 10.1358/dnp.2009.22.2.1303818
11. Negera E, Walker SL, Girma S, et al. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia. PloS Negl Trop Dis. 2017;13;11(10):e0066011. doi: 10.1371/journal.pntd.0066011
12. Sanghi S. IAL Textbook of Leprosy. Med J Armed Forces India. 2010;66(3):284. doi:10.1016/s0377-1237(10)80066-8
13. Di Lernia V. Linear and whorled hypermelanosis. Pediatr Dermatol. 2007;24(3):205–210. doi: 10.1111/j.1525-1470.2007.00387.x

14. Pratiwi FD, Agusni I, Staf D, et al. Kelainan Sistemik dan Laboratoris pada Pasien Kusta dengan Reaksi Tipe 2 (Erythema Nodosum Leprosum) (Systemic and Laboratory Abnormalities of Leprosy Patients with Type 2 Reaction [Erythema Nodosum Leprosum]). 2013.2

15. Županić-Krmek, Sučić M, Bekić D. Anemia of chronic disease: illness or adaptive mechanism. Acta Clin Croat. 2014;53(3):348–354.

16. Murray J, Barbara JA, Dunkley SA, et al. Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood. 1997;90(7):2772–2783.

17. Amulic B, Cazalet C, Hayes GL, et al. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30(1):459–489. doi: 10.1146/annurev-immunol-020711-074942

18. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy—a review. Epilepsy Res. 2009;85(1):31–45. doi: 10.1016/j.eplepsyres.2009.03.003

19. Mahajan VK. Slit-skin smear in leprosy: lest we forget it! Indian J Lepr. 2013;85(4):177–183. doi: 10.1029/92JA01839

20. Ishii N, Mori S, Nagaoka Y, Suzuki K. Report of the Ninth meeting of the WHO Technical Advisory Group of Leprosy Control. Nihon Hansenbyo Gakkai Zasshi = Japanese Journal of Leprosy: Official Organ of the Japanese Leprosy Association. 2009;78(1):75–88. doi:10.5025/hansen.78.75

21. Nery JA Da Costa, Sales AM, Illarramendi X, et al. Contribution to diagnosis and management of reactional states: A practical approach. An. Bras. Dermatol. [online]. 2006;81(4):367–375. doi: 10.1590/S0365-05962006000400010

22. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021–9026. doi: 10.1073/pnas.0812690106

23. Hobbenaghi R, Javanbakht J, Hosseini E, et al. Neuropathological and neuroprotective features of vitamin B12 on the dorsal spinal ganglion of rats after the experimental crush of sciatic nerve: an experimental study. Diagn Pathol. 2013;31(8):123. doi: 10.1186/1746-1596-8-123

24. Lopatina T, Kalinina N, Karagyaur M, et al. Adipose-derived stem cells stimulate regeneration of peripheral nerves: BDNF secreted by these cells promotes nerve healing and axon growth de novo. PLoS One. 2011;14;6(3):e17899. doi: 10.1371/journal.pone.0017899

Information about the author

Khairuddin Djawad — Doctor; address: 10 Perintis Kemerdekaan street, 90245, Makassar, Indonesia; ORCID iD: https://orcid.org/0000-0002-4569-6385; e-mail: duddin@ymail.com

Статья поступила в редакцию: 18.12.2020
Принята к публикации: 20.01.2021
Дата публикации: 26.02.2021

Submitted: 18.12.2020
Accepted: 20.01.2021
Published: 26.02.2021